Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
Search or
𝛼
SK
SIGN UP
SIGN IN
bullish
Jiangsu Hengrui Pharmaceuticals
Watchlist
Hengrui Pharma (1276 HK): Trying to Achieve Total Global Index Inclusion
Index Rebalance
354 Views
26 May 2025 22:04
Hengrui Pharma's (1276 HK) inclusion in Global Standard in August 2025 is less likely than its forecasted addition to Global All-World in December 2025 due to low float cap.
What is covered in the Full Insight:
Overview
The Offering
Free Float
Index Inclusion
Summary
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Japan
Index Rebalance
Equity Bottom-Up
South Korea
Event-Driven
Singapore
Sell / Short Ideas
Japan Small Cap Growth
China
India
Trending Insights
More »
Shibaura Electronics (6957 JP): Yageo Poised to Secure FEFTA Approval
Nikkei 225 Index Rebalance Sep25: Performance of Potential Adds/Deletes & Positioning
HHI–Mipo Merger Swap: Deal Mechanics & Spread Play Opportunities
A Merger Between HD Hyundai Heavy Industries and HD Hyundai Mipo
Fast Retailing (9983 JP) Tactical Outlook: Turning OVERSOLD, Potential BUY Ahead of Sep-25 Rebalance
Top Unpaywalled Insights
More »
A Monetary View on US Inflation
At the US-Korea Summit, Samsung’s Next Move Could Reshape the US Chipboard
DeFi, On-Chain Truth, and the Petrodollar 2.0
[IO Technicals 2025/34] Iron Ore Braces for Bullish Shift After Six-Day Slide
SoilBuild Construction Group Limited: Soilbuild’s 1HFY25 Earnings Soar Past FY24
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Hengrui Pharma (1276 HK): Trying to Achieve Total Global Index Inclusion
26 May 2025
Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey
22 May 2025
Jiangsu Hengrui Pharma H Share Listing (1276 HK): Trading Debut
22 May 2025
Foshan Haitian Flavouring A/H Listing - Strong Brand but Sales Have Been Slowing Down
05 Feb 2025
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.56.4
x